EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Open Access · CC BY-NC 4.0

Population pharmacokinetics of eptinezumab in paediatric patients with migraine and dose selection for phase 3 paediatric migraine studies

Johan Areberg iD, Monika Rosen, Annika Lindsten, Marianne Dragheim, Janka Ryding

Basic & Clinical Pharmacology & Toxicology · 2024

DOI: 10.1111/bcpt.14076 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Basic & Clinical Pharmacology & Toxicology, 2024. Verfasst von Johan Areberg und 4 weiteren Autor:innen. Beteiligte Einrichtung: H. Lundbeck A/S, Copenhagen, Denmark. Hauptthemen laut MEDLINE: Migraine Disorders, Models, Biological, Antibodies, Monoclonal, Humanized, Body Weight. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: H. Lundbeck A/S.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This population pharmacokinetics (PopPK) analysis of eptinezumab used data from a paediatric study and a prior adult PopPK model to compare eptinezumab pharmacokinetics between adult and paediatric populations to determine dose recommendations for the phase 3 paediatric studies in migraine. The data consisted of 16 adolescents and 12 children with migraine, with corresponding demographics and 278 plasma concentrations in total. PopPK analysis was performed through nonlinear mixed effect modelling and with prior knowledge taken from a previous PopPK model in adults. A two‐compartment model—adjusted for body weight impact on clearances and volumes of distributions and scaled to the power of 0.75 and 1.0, respectively—was found to adequately describe the paediatric pharmacokinetic data. The simulated population showed overlap in area under the plasma concentration–time curve and maximum plasma concentration between the paediatric and adult populations, with paediatric exposures within 10%–15% above adult levels on average. To provide comparable exposure to the approved adult doses, weight‐based dosing adjustments are recommended for paediatric patients weighing ≤40 kg, while no adjustments are needed for patients weighing >40 kg. These results support the dosing strategy being used in the ongoing efficacy and safety studies with eptinezumab in children and adolescents with migraine.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Migraine DisordersModels, BiologicalAntibodies, Monoclonal, HumanizedBody WeightHumansAdolescentChildMaleFemaleArea Under CurveDose-Response Relationship, DrugAdultAge FactorsDrug Dosage Calculations

Stichwörter der Autor:innen

CGRPeptinezumabmigrainepaediatricspopulation pharmacokinetics

Substanzen

Antibodies, Monoclonal, Humanizedeptinezumab

Autor:innen und Institutionen

  • H. Lundbeck A/S, Copenhagen, Denmark.

ORCID-Profile: Johan Areberg

Förderung

  • H. Lundbeck A/S

Zitieren

APA

Areberg, J., Rosen, M., Lindsten, A., Dragheim, M., & Ryding, J. (2024). Population pharmacokinetics of eptinezumab in paediatric patients with migraine and dose selection for phase 3 paediatric migraine studies. Basic & Clinical Pharmacology & Toxicology. https://doi.org/10.1111/bcpt.14076

Vancouver

Areberg J, Rosen M, Lindsten A, Dragheim M, Ryding J. Population pharmacokinetics of eptinezumab in paediatric patients with migraine and dose selection for phase 3 paediatric migraine studies. Basic & Clinical Pharmacology & Toxicology. 2024. doi:10.1111/bcpt.14076

BibTeX
@article{Areberg2024,
  author = {Areberg, Johan and Rosen, Monika and Lindsten, Annika and Dragheim, Marianne and Ryding, Janka},
  title = {Population pharmacokinetics of eptinezumab in paediatric patients with migraine and dose selection for phase 3 paediatric migraine studies},
  journal = {Basic & Clinical Pharmacology & Toxicology},
  year = {2024},
  doi = {10.1111/bcpt.14076}
}
Kostenlos starten →